Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
206 hedge funds and large institutions have $2.79B invested in Portola Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 67 increasing their positions, 66 reducing their positions, and 17 closing their positions.
159% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 17
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
45% more capital invested
Capital invested by funds: $1.92B → $2.79B (+$867M)
14% more funds holding
Funds holding: 180 → 206 (+26)
12% more call options, than puts
Call options by funds: $98M | Put options by funds: $87.2M
2% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 66
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$42.2M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$21M |
| 3 |
D.E. Shaw & Co
New York
|
+$20.8M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.8M |
| 5 |
Renaissance Technologies
New York
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$68.1M |
| 2 |
DM
Deerfield Management
New York
|
-$41.3M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$21.7M |
| 4 |
JP Morgan Chase
New York
|
-$13.9M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
-$13.2M |
PTLA Hedge Fund Activity: Q2 2017 in Review
206 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2017, worth a combined $2.79B — up 45% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new PTLA positions and 17 closed out — a net gain of 27 holders — while 67 added to existing stakes and 66 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $42.2M. The largest seller was Temasek Holdings, cutting an estimated $68.1M.
- 206 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2017, up from 180 in Q1 2017.
- Funds reported $2.79B of Portola Pharmaceuticals, Inc. stock for Q2 2017, up 45% quarter-over-quarter.
- 44 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2017 and 17 closed out, a net change of +27 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q2 2017 was PFM Health Sciences, an estimated $42.2M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q2 2017 was Temasek Holdings, an estimated $68.1M sold.
Based on aggregated 13F filings for Q2 2017.